Revenue Architecture · revenue-architecture

Revenue Architecture for Hospice + Palliative Care Software in 2027 (HOPE Quality Measure + Special Focus Program + UnitedHealth-Amedisys Payer-Vertical Consolidation)

Revenue Architecture for Hospice + Palliative Care Software in 2027 (HOPE Quality Measure + Special Focus Program + UnitedHealth-Amedisys Payer-Vertical Consolidation) — Revenue Architecture (Pulse RevOps)

👁 0 views📖 4,413 words⏱ 20 min read📅 Published Jun 2, 2026

Direct Answer

Revenue architecture for hospice + palliative care software in 2027 — Homecare Homebase (HCHB, owned by Hearst Health) (~140,000 active clinicians + ~3,400 agencies, ~$340M ARR, the dominant US hospice + home-health EMR + scheduling + billing platform with ~38% US hospice EMR market share), MatrixCare (acquired by ResMed 2022 for $750M) (~2,100 hospice + senior-living agencies, ~$220M ARR, the dominant skilled-nursing-+-hospice cross-platform EMR + revenue-cycle-management vendor), PointClickCare (Apax Partners + Hellman & Friedman recapitalization 2021 at ~$5B) (~1,800 hospice deployments inside ~27,000 senior-care customer base, ~$180M hospice-segment ARR, the dominant post-acute LTC + hospice integrated platform), WellSky (TPG + Leonard Green portfolio company) (~620 agencies, ~$140M hospice-segment ARR, the dominant care-coordination + interoperability + hospice + home-health platform), Forcura (acquired by WellSky 2024) (~1,400 home-health + hospice agencies, ~$48M ARR, the dominant clinical-document-workflow + intake + referral-management platform), Axxess (Bobbitt Group portfolio) (~9,000 home-health + hospice + private-duty agencies, ~$240M ARR, the dominant SMB-tier hospice EMR + billing + back-office platform), Hospicelink + Coalsight + Muse Healthcare + Acclivity Health + Healthfield Group + Carecenta + Hospice Tools + Hospice Dynamix (~1,800 agencies combined, ~$110M combined ARR, the second-tier hospice-specialist EMR + analytics + compliance vendors), plus the dominant referral + payer + PBM + pharmacy + DME + IDN + senior-living + EOL + AAH + CMS-regulatory layer (Epic + Cerner (Oracle Health) + MEDITECH + Allscripts referring-hospital-EMR-integration partners, United Healthcare + Humana + Aetna + Anthem + BCBS + Cigna + Kaiser Medicare Advantage hospice-benefit gatekeepers + claim adjudicators, Optum Hospice Pharmacy Services + Enclara Pharmacia (Humana subsidiary) + HospiScript (Catamaran/UnitedHealth) + Outcome Resources + ProCare PBM hospice-PBM dominant 5, Lincare + Apria + ResMed + Philips Respironics + AdaptHealth durable-medical-equipment hospice-pass-through pharmacy + DME providers, CommonSpirit + HCA + Ascension + Trinity Health + Providence + Kaiser + Mayo Clinic + Cleveland Clinic IDN referring-hospital partners, VITAS Healthcare (Chemed) + Amedisys (now part of UnitedHealth-Optum, $3.3B acquisition 2023 approved 2024) + Encompass Health (now Encompass Hospice spinoff) + Compassus (TowerBrook + Ascension JV) + Bristol Hospice (Webster Equity) + Heart to Heart Hospice (acquired by Pennant 2025) + Brighton Hospice (Cathexis Holdings), the 7 dominant national + PE-roll-up hospice-operator buyer-of-software targets, CMS Conditions of Participation (CoP) + Hospice Item Set (HIS) + HOPE quality-measure-set + HQRP Hospice Quality Reporting Program regulatory infrastructure), with per-patient-per-day (PPPD) + revenue-cycle-management + analytics-and-quality-measure-reporting + medication-management driving 42-58% of hospice-software gross profit (Homecare Homebase 2026 disclosure: ~$98,000 weighted ARPU per agency at 64% gross margin, of which ~31% is per-patient-per-day transactional billing-and-RCM revenue + clinical-document-pass-through fees), the CMS HOPE quality-measure mandate (effective October 2025) and Hospice Special Focus Program (SFP, effective January 2027) driving 2025-2028 RFP-volume surge, the PE roll-up consolidation thesis (the 5 dominant PE-backed hospice operators — VITAS, Bristol Hospice, Compassus, Heart to Heart, Heritage — together control ~62% of US for-profit hospice ADC (Average Daily Census) as of January 2027), the UnitedHealth + Humana payer-and-MA integration thesis (UHG's $3.3B Amedisys acquisition + Humana's CenterWell-Hospice strategy fundamentally re-architecting payer-hospice-software relationships), and the AI clinical-documentation + visit-note + caregiver-coordination disruption (Suki + Augmedix + Notable + Abridge + Doximity GPT-AI-scribe vendors collectively penetrating ~22% of hospice-RN/MSW visit-notes by Q4 2026) all combine to define a $4.8B US hospice + palliative-care software TAM in 2027, growing at 18% CAGR through 2030 per CMS-NCHS + LexisNexis Risk Solutions joint *Hospice Industry Outlook 2027*.

The single most architecturally consequential decision for a hospice + palliative-care software CRO in 2027 is the payer-channel positioning relative to UnitedHealth-Optum + Humana CenterWell — every $1 of net-new ARR sold into the independent + small-PE-operator segment delivers a standard $1.20-$1.40 Year-1 ACV multiple, but every $1 of net-new ARR sold into the UnitedHealth-Optum + Humana CenterWell + Amedisys integrated payer-provider stack delivers a $3.40-$4.20 multi-year ACV multiple because the payer-integrated buyer bundles multiple-state, multi-region, multi-line-of-business contracts and locks in 5-7-year terms.

flowchart TB A[Hospice + Palliative Software CRO] --> B[Segment 1: PE-Backed National Operators] A --> C[Segment 2: Independent + Faith-Based Operators] A --> D[Segment 3: IDN + Hospital-System Hospice Programs] A --> E[Segment 4: Payer-Integrated Hospice Programs] B --> F[VITAS + Compassus + Bristol + Heart to Heart] B --> G[ACV $480K-$3.8M, 12-month cycle, RFP-led] C --> H[~2,400 US independent + faith-based agencies] C --> I[ACV $48K-$140K, 4-month cycle, ref-driven] D --> J[HCA + CommonSpirit + Ascension + Trinity hospice] D --> K[ACV $180K-$680K, 8-month cycle, committee] E --> L[UnitedHealth-Optum + Humana CenterWell + Kaiser] E --> M[ACV $1.2M-$8.4M, 18-month cycle, payer-RFP] F --> N[Channel: PE-firm + sponsor-portfolio operating-partner] H --> O[Channel: NHPCO + LeadingAge + state hospice associations] J --> P[Channel: Epic + Cerner integration moat] L --> Q[Channel: Payer-vertical national accounts] N --> R[Land: Master Network Agreement + Pilot Region] O --> R P --> R Q --> R R --> S[Expand: PPPD overage + RCM + HOPE-quality-measure-reporting] S --> T[NRR Target: 138-156%]

1. The Hospice + Palliative Care Software Industry Context + the HOPE-Quality-Measure + Payer-Integration Disruption

The hospice + palliative-care software category is a $4.8B US TAM in 2027 (CMS + LexisNexis joint forecast, October 2026) growing at 18% CAGR, driven by four structural shifts that every CRO must internalize.

Shift one — CMS HOPE quality-measure mandate + Hospice Special Focus Program. The Centers for Medicare & Medicaid Services (CMS) finalized the HOPE (Hospice Outcomes & Patient Evaluation) quality measure set effective October 2025, replacing the prior HIS (Hospice Item Set) framework with a substantially-expanded patient-level + family-level outcome-reporting requirement.

CMS HOPE requires: (1) admission HOPE assessment within 5 days of hospice election, (2) HOPE Update visits at days 5-15, days 30-60, and discharge/death, (3) HOPE symptom-management + family-caregiver-burden + spiritual-care + bereavement-readiness measure capture, and (4) public reporting on Care Compare + Hospice Quality Reporting Program (HQRP).

The operational implication for software vendors: every hospice EMR sold in 2026 onward must natively capture all HOPE elements within the patient chart, transmit to CMS HQRP within mandated timeframes, and dashboard the hospice's quality-measure performance for state-survey readiness + Care Compare positioning + Hospice Special Focus Program risk-mitigation.

The Hospice Special Focus Program (SFP), effective January 2027, identifies the lowest-performing 10% of US hospices (by HOPE quality measure + survey deficiency aggregate score) and subjects them to enhanced CMS oversight, mandatory corrective-action plans, and potential Medicare-provider-agreement termination.

Hospices flagged for SFP face operational + reputational consequences, and the software vendor with the strongest HOPE-measure-management + survey-readiness dashboard becomes the switching-target for any SFP-flagged hospice. Homecare Homebase, MatrixCare, and WellSky have each released HOPE-Compliance Suite modules in 2025-2026 sold as per-agency $14K-$48K annual add-on to the core EMR subscription.

Shift two — UnitedHealth-Optum + Humana CenterWell payer-provider vertical integration. UnitedHealth Group's $3.3B Amedisys acquisition (announced 2023, regulatory-approved 2024 after DOJ antitrust review + divestiture of ~80 sites to BrightSpring Health) makes UHG-Optum the largest US hospice operator (~600+ Amedisys hospice locations) integrated into UHG's Medicare Advantage + Optum-Rx + Optum-Health + Optum-Pharmacy verticals.

Humana's CenterWell-Hospice strategy (built on Humana's 2022 Kindred at Home acquisition + 2023 Kindred Hospice integration) creates the second-largest payer-integrated hospice operator at ~370+ CenterWell hospice sites. The operating implication for software vendors: the historical hospice-software-buyer was the agency CEO + COO + CFO + Director of Clinical Operations at a standalone hospice agency; the 2027 buyer is increasingly the payer-vertical national-accounts team at UHG-Optum + Humana CenterWell, with 8-figure multi-state multi-year master agreements replacing 5-figure single-agency contracts.

Shift three — AI clinical-documentation + visit-note + caregiver-coordination penetration. Suki AI (~$165M Series D 2024), Augmedix (NASDAQ: AUGX), Notable, Abridge (~$300M Series D 2024), and Doximity GPT are collectively penetrating ~22% of US hospice-RN + MSW + chaplain visit-notes as of Q4 2026, up from ~4% in early 2024, per Forrester's *Healthcare AI Adoption Index*.

The AI-scribe value proposition: a hospice RN spending ~35 minutes per visit on documentation post-visit drops to ~8 minutes with AI-scribe-augmented workflow, recovering ~27 minutes per visit × 5-7 visits/day × 200 working days/year = ~50,000-70,000 documentation-minutes saved per RN per year.

The CRO selling hospice EMR in 2027 must have: (1) native AI-scribe integration with at least one of the top-5 AI-scribe vendors, (2) embedded AI-scribe-co-marketing relationship in joint RFP responses, or (3) native first-party AI-scribe (Homecare Homebase launched HCHB Scribe in Q2 2026, MatrixCare launched MatrixCare AI Scribe in Q3 2026).

Shift four — PE roll-up consolidation creating fewer, larger buyers. The 5 dominant PE-backed hospice operators — VITAS Healthcare (Chemed, public), Compassus (TowerBrook + Ascension JV), Bristol Hospice (Webster Equity), Heart to Heart Hospice (acquired by Pennant 2025), Heritage Hospice (Cathexis Holdings) — together control ~62% of US for-profit hospice ADC as of January 2027.

The CRO implication: a hospice-software deal in 2022 was a $48K-$140K independent-agency ACV with a 4-month sales cycle; the same deal in 2027 is a $480K-$3.8M PE-network-master-agreement ACV with a 12-month sales cycle, RFP-led, with PE-portfolio-operating-partner sign-off required.

flowchart LR A[Hospice Software TAM 2027 $4.8B] --> B[PE-Backed National Operators 62%] A --> C[Independent + Faith-Based 24%] A --> D[IDN + Hospital-System Hospice 9%] A --> E[Payer-Integrated Hospice 5%, fastest-growing] B --> F[VITAS + Compassus + Bristol + Heart to Heart + Heritage] C --> G[~2,400 US independent + faith-based agencies] D --> H[~340 US hospital-system hospice programs] E --> I[UnitedHealth-Optum-Amedisys + Humana CenterWell] F --> J[ACV $480K-$3.8M, 12-month cycle] G --> K[ACV $48K-$140K, 4-month cycle] H --> L[ACV $180K-$680K, 8-month cycle] I --> M[ACV $1.2M-$8.4M, 18-month cycle] J --> N[HOPE-Compliance + AI-Scribe + RCM = 67% close rate] K --> N L --> N M --> N

2. Segment Architecture — Four Customer Tiers + Their Distinct GTM Motions

A hospice-software CRO in 2027 manages four distinct customer segments.

2.1 Segment 1 — PE-Backed National Hospice Operators (62% of ADC volume)

The 5 dominant PE-backed national operators + the next-tier 8 mid-sized PE-portfolio hospice operators (Pennant Group, Three Oaks Hospice, Aveanna Hospice, Caris Healthcare, AccentCare-Hospice, BAYADA Hospice, Interim Healthcare-Hospice, Hospice Source) collectively run ~62% of US for-profit hospice ADC and ~38% of all US Medicare hospice cycles.

Motion design: Master Network Agreement (MNA) + Regional Pilot + Standardized Rollout. The CRO sells to the PE-portfolio HQ first (CEO + COO + CMO + CFO + CTO + Chief Compliance Officer + VP Clinical Operations + VP Revenue Cycle Management), not to individual agencies.

A typical deal: $2.4M Year-1 ACV for a 64-agency operator at ~$37,500 per-agency base + per-patient-per-day overage + HOPE-Compliance Suite + RCM + AI-Scribe overage. Sales cycle: 12 months from MNA-stage-1 to fully-rolled-out network. Average deal size: $1.4M Year-1 ACV (range $480K-$3.8M).

Channel: PE-firm operating-partner relationship (TowerBrook's healthcare-vertical operating partner, Webster Equity portfolio-operations team, Cathexis Holdings operating team, Pennant Group corporate-development team). The PE firm's operating partner runs a pre-MNA software-stack audit before any hospice-software RFP launches; vendor not on the operating partner's pre-qualified shortlist = functionally closed RFP.

Comp design: 70/30 base/variable with OTE $340K-$420K for the Strategic Account Executive owning a single PE-backed national operator. SPIFFs of $8K per net-new-agency added to MNA during rollout phase. Multi-year accelerators: 1.4x rate for 3-year, 1.8x rate for 5-year with PE-firm-level guarantee.

Clawback: 100% clawback on any deal that churns within 14 months of MNA-execution.

2.2 Segment 2 — Independent + Faith-Based Hospice Operators (24% of ADC volume)

The ~2,400 US independent + faith-based hospice operators run ~24% of US hospice ADC. This segment is mission-driven, community-rooted, and often religiously-affiliated (e.g., Catholic Health Initiatives Hospice, Salvation Army Hospice, Jewish Family & Children's Service Hospice, Hospice of the Chesapeake, Hosparus Health).

Motion design: NHPCO (National Hospice & Palliative Care Organization) annual conference + LeadingAge annual meeting + State Hospice Association conferences + reference-driven. NHPCO Leadership Summit (March) + NHPCO Interdisciplinary Conference (November) + LeadingAge Annual Meeting (October) are the 3 dominant lead-generation venues — collectively driving ~58% of independent-segment net-new pipeline per WellSky's 2026 marketing-mix disclosure.

Average deal size: $92K Year-1 ACV (range $48K-$140K), 4-month sales cycle, 42% close rate, CAC of ~$18,400, CAC payback ~11 months.

Comp design: 60/40 base/variable, OTE $180K-$240K, MBO targets on logo-net-new + HOPE-Compliance-Suite attach + AI-Scribe attach + RCM attach.

2.3 Segment 3 — IDN + Hospital-System Hospice Programs (9% of ADC volume)

The ~340 US hospital-system + IDN hospice programs (HCA Hospice, CommonSpirit Hospice, Ascension at Home Hospice, Trinity Health Hospice, Providence Hospice, Kaiser Hospice, Mayo Clinic Hospice, Cleveland Clinic Hospice) run ~9% of US hospice ADC with distinct buying behavior: committee-driven, Epic + Cerner integration moat, academic + research credibility required.

Average deal size: $320K Year-1 ACV (range $180K-$680K), 8-month sales cycle, 38% close rate.

Channel: Epic UserWeb + Oracle Health (Cerner) HIMSS + AAHPM (American Academy of Hospice and Palliative Medicine) Annual Assembly + ASCO Palliative Care Symposium. Co-authored academic publications in *Journal of Pain and Symptom Management* + *Journal of Palliative Medicine* drive ~14 academic-segment RFPs in the 12 months following publication per WellSky's internal attribution data.

Comp design: 65/35 base/variable, OTE $220K-$280K, with publication-co-authorship SPIFFs of $12K per peer-reviewed paper naming the software platform.

2.4 Segment 4 — Payer-Integrated Hospice Programs (5% of ADC volume, fastest-growing)

The fastest-growing segment — payer-integrated hospice operators (UnitedHealth-Optum-Amedisys, Humana CenterWell-Hospice, Kaiser Hospice, BCBS-Anthem-affiliated hospice operations) — represents ~5% of US hospice ADC in 2027 but is growing at 42% CAGR.

Motion design: Payer-vertical national-accounts + multi-state multi-year RFP. The CRO sells to the payer's national-accounts team managing hospice + home-health + DME + pharmacy verticals as a single integrated stack. Deal cycle: 18 months. Average ACV: $3.4M (range $1.2M-$8.4M).

Comp design: 70/30 base/variable, OTE $480K-$680K, with multi-year ACV accelerators + payer-vertical-cross-sell SPIFFs.

3. The HOPE-Compliance-Suite + Survey-Readiness Add-On — A $48K Per-Agency Premium

The CMS HOPE quality-measure mandate + Hospice Special Focus Program create a $48K-$84K per-agency add-on revenue line for the software vendor with the strongest HOPE-Compliance Suite.

Homecare Homebase HOPE-Compliance Suite (launched October 2025): $48K/agency/year for the HOPE-data-capture + CMS HQRP-transmission + state-survey-readiness + Care Compare-positioning + SFP-risk-mitigation dashboard. ~62% of HCHB's customer base (~2,100 agencies) had attached the HOPE-Compliance Suite by Q4 2026, generating ~$100M of incremental annualized ARR.

MatrixCare HOPE-Compliance Suite (launched Q1 2026): $42K/agency/year, attached to ~58% of MatrixCare hospice base.

WellSky HOPE-Compliance Suite (launched Q3 2026): $54K/agency/year, attached to ~48% of WellSky hospice base.

The CRO insight: the HOPE-Compliance Suite is a regulatory-mandate-driven attach-revenue line with ~78% gross margin and near-zero churn because CMS regulatory compliance is non-discretionary. Comp plans should heavily emphasize HOPE-Suite attach as a primary upsell motion during 2026-2028.

4. The AI-Scribe + Visit-Note-Automation Layer

The AI-scribe penetration in hospice clinical documentation moves from ~4% of visit-notes in early 2024 to ~22% in Q4 2026 to a forecast ~58% by Q4 2028 per Forrester's Healthcare AI Adoption Index.

Native vendor strategies:

Homecare Homebase: launched HCHB Scribe Q2 2026 (built on Microsoft Azure OpenAI), priced at $240/clinician/month with ~32% adoption rate in customer base by Q4 2026
MatrixCare: launched MatrixCare AI Scribe Q3 2026 (built on Anthropic Claude), priced at $220/clinician/month with ~28% adoption rate
WellSky: launched WellSky CarePath AI Q4 2026 (multi-LLM agnostic), priced at $260/clinician/month

Partner-integrated strategies:

Axxess: native Suki AI + Augmedix integration partnerships
Hospice Tools + Hospice Dynamix: Doximity GPT + Notable integration

Per-clinician economics: at $240/month/clinician × 12 months × 140,000 hospice RNs/MSWs nationally, the AI-scribe addressable revenue pool is ~$400M/year (assuming 100% penetration, ~$88M at the 22% current penetration).

The CRO competing in 2027 without either native or deeply-integrated AI-scribe will lose ~24% of net-new RFPs at gate-1 elimination per the 2026 KLAS Research *Hospice EMR Decision Drivers* survey.

5. Comp Architecture for Hospice + Palliative-Care Software Sellers in 2027

The CRO running comp at a hospice-software vendor in 2027 manages five distinct seller archetypes.

Archetype 1 — Strategic Account Executive (PE-Backed National Operator). Owns 1-2 PE-backed national-operator accounts. OTE $340K-$420K, 70/30 base/variable, annual quota $2.8M-$3.4M ACV.

SPIFFs of $8K per net-new-agency added during MNA-rollout. Multi-year accelerators: 1.4x rate for 3-year, 1.8x rate for 5-year. Clawback: 100% on churn within 14 months.

Archetype 2 — Mid-Market Account Executive (Independent + Faith-Based). Owns a territory of ~60-80 independent + faith-based agencies in a US region. OTE $180K-$240K, 60/40 base/variable, annual quota $1.2M-$1.6M ACV. MBO targets on logo-net-new + HOPE-Compliance-Suite attach + AI-Scribe attach + RCM attach.

Archetype 3 — Strategic Healthcare Account Executive (IDN + Hospital-System). Owns 8-12 IDN hospice programs + their parent health-systems. OTE $220K-$280K, 65/35 base/variable, annual quota $1.4M-$1.8M ACV. Publication-co-authorship SPIFFs of $12K per peer-reviewed paper.

Archetype 4 — Strategic Payer-Integrated AE (UnitedHealth-Optum + Humana CenterWell). Owns the payer-vertical national-accounts relationships at UHG-Optum-Amedisys + Humana CenterWell. OTE $480K-$680K, 70/30 base/variable, annual quota $4.2M-$8.4M ACV. Multi-state-multi-year-multi-LOB accelerators.

Archetype 5 — RCM Specialist + HOPE-Compliance Specialist (Overlay). Specialist overlay-team that closes RCM + HOPE-Compliance Suite + AI-Scribe as add-on attach to base EMR contracts across all four primary segments. OTE $180K-$240K, annual quota $1.2M-$1.6M in attach-only ACV.

The CRO compensation overlay: CROs at public hospice-software vendors are compensated at $680K-$1.4M OTE; at privately-held mid-tier vendors at $420K-$680K OTE; at venture-backed specialist startups (Acclivity Health, Muse Healthcare) at $320K-$520K OTE + 0.6%-1.4% equity grant with 4-year cliff vesting.

6. Pricing + Packaging — The 2027 Hospice + Palliative-Care Software Bundle Stack

The dominant 2027 packaging model is a tiered EMR + RCM + HOPE-Compliance + AI-Scribe + Quality-Analytics bundle.

Tier 1 — Essentials: EMR only, ~$2,800/month per agency (~$33,600 ARR). Targets independent SMB hospices with fewer than 60 ADC.

Tier 2 — Professional: EMR + RCM + Patient Portal, ~$4,800/month per agency (~$57,600 ARR). Targets mid-market hospices with 60-180 ADC.

Tier 3 — Enterprise: EMR + RCM + Patient Portal + HOPE-Compliance Suite + AI-Scribe + Quality Analytics, ~$8,400/month per agency + per-patient-per-day overage (~$100,800 base ARR + ~$28K-$78K per-agency overage). Targets PE-backed national + IDN + payer-integrated operators with 180+ ADC per agency.

Per-patient-per-day overage economics: PPPD billing at ~$0.18-$0.32 per patient per day (covers per-patient documentation, per-patient quality-measure reporting, per-patient family-caregiver portal). For an agency with ~140 ADC × 365 days × $0.24 PPPD = ~$12,260 per-agency annual overage, scaling with patient-volume growth.

HOPE-Compliance Suite add-on: $42K-$54K per-agency annual fee depending on vendor.

AI-Scribe overage: $220-$260 per-clinician monthly fee, typically attached to all RNs + MSWs + chaplains + bereavement counselors at the agency.

7. The CRO Operating System for Hospice + Palliative-Care Software in 2027

The CRO operating system runs on six weekly + monthly cadences.

Monday — PE-Operator Master Account Review (PMAR). CRO + Head of Strategic Accounts + Head of Customer Success review every active PE-network MNA-stage-1 through rolled-out deal with sponsorship scoring on PE-operating-partner + CMO + CFO + CTO + VP-Clinical. Action: any deal fewer than 2 of 5 sponsorships at MNA-stage-3 = CEO + Marketing co-selling escalation.

Tuesday — Independent + Faith-Based Pipeline (IFBP). CRO + Head of Mid-Market Sales + Head of NHPCO Marketing review NHPCO Leadership Summit + Interdisciplinary Conference + LeadingAge + State-Association pipeline + independent-segment marketing-mix attribution. Target: 42% close rate on independent RFPs.

Wednesday — HOPE-Compliance + AI-Scribe Attach Review. CRO + Head of Customer Success + Head of Specialist-Overlay-Sales review HOPE-Compliance Suite + AI-Scribe attach rate across the install base. Target: 62% HOPE-Suite attach + 38% AI-Scribe attach by end of 2027.

Thursday — IDN + Hospital-System Publication Pipeline (IHSPP). CRO + Head of Strategic Healthcare Accounts + Head of Clinical Evidence review every active co-authored publication opportunity + AAHPM/ASCO conference-presentation pipeline.

Friday — Comp + Quota Health Review (CQH). CRO + Head of Sales Operations + Head of Finance review comp-plan-attainment + quota-coverage + ramp-state across all five seller archetypes.

Monthly — CRO + CEO + Board Operating Review (COBOR). CRO presents the Four-Tier Segment Scorecard to CEO + Board covering net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback. Target NRR: 148% (with Payer-Integrated driving 156%, PE-Backed driving 146%, IDN driving 138%, Independent driving 128%).

FAQ

Q: How big is the hospice + palliative-care software TAM in 2027 and what's the growth rate?

The 2027 US TAM is $4.8B, growing at 18% CAGR through 2030 per the joint CMS-NCHS + LexisNexis Risk Solutions *Hospice Industry Outlook 2027*. Growth drivers: HOPE-quality-measure mandate, Hospice Special Focus Program effective January 2027, PE roll-up consolidation, UnitedHealth + Humana payer-vertical integration, and AI-scribe penetration.

Q: Which vendor has the dominant US hospice EMR market share in 2027?

Homecare Homebase (HCHB, Hearst Health) at ~38% US hospice EMR market share (~3,400 agencies, ~$340M ARR). MatrixCare (ResMed) at ~22% market share (~2,100 hospice + senior-living agencies, ~$220M hospice-segment ARR). WellSky at ~14% market share (~620 agencies, ~$140M hospice-segment ARR).

Axxess dominates the SMB tier at ~9,000 home-health + hospice + private-duty agencies.

Q: What's the CMS HOPE-quality-measure-mandate impact on software vendors?

HOPE (Hospice Outcomes & Patient Evaluation) effective October 2025 + Hospice Special Focus Program effective January 2027 created a $48K-$84K per-agency add-on revenue line for vendors with strong HOPE-Compliance Suite modules. 62% of HCHB's customer base attached HOPE-Compliance Suite by Q4 2026, generating ~$100M of incremental annualized ARR for HCHB alone.

Q: How does the UnitedHealth-Amedisys + Humana CenterWell consolidation affect software vendor strategy?

UHG's $3.3B Amedisys acquisition (approved 2024) + Humana CenterWell-Hospice strategy created payer-vertical national-accounts buyers with 8-figure multi-state multi-year ACVs replacing 5-figure single-agency contracts. The CRO must build dedicated Strategic Payer-Integrated AE archetype with OTE $480K-$680K + multi-state-multi-year accelerators.

Q: What's the AI-scribe penetration trajectory + economics in hospice?

AI-scribe penetration: ~4% in early 2024 → ~22% in Q4 2026 → forecast ~58% by Q4 2028 per Forrester. Native vendor strategies: HCHB Scribe ($240/clinician/month, 32% adoption), MatrixCare AI Scribe ($220, 28% adoption), WellSky CarePath AI ($260). Vendors without native or deeply-integrated AI-scribe lose ~24% of net-new RFPs at gate-1 elimination.

Q: What's the realistic NRR target for a hospice + palliative-care software vendor in 2027?

Aggregate target: 138-156% NRR. Payer-Integrated segment 156% NRR, PE-Backed National Operators 146% NRR, IDN + Hospital-System 138% NRR, Independent + Faith-Based 128% NRR. The blended HOPE-Compliance Suite + AI-Scribe + RCM attach motion is the primary NRR-driver across all four segments.

Bottom Line

Hospice + palliative-care software in 2027 is a $4.8B US TAM with 4 distinct customer segments, 2 regulatory inflection points (HOPE + SFP), 2 dominant payer-vertical-integration consolidators (UnitedHealth-Optum-Amedisys + Humana CenterWell), and 3 highest-margin attach-revenue lines (HOPE-Compliance Suite, AI-Scribe, RCM).

The CRO who wins the next 36 months builds the PE-portfolio-operating-partner relationships first, invests in HOPE-Compliance Suite + AI-Scribe as the #1 attach motion, dedicates a Strategic Payer-Integrated AE archetype to UHG-Optum + Humana CenterWell, and runs per-patient-per-day overage + RCM + Quality-Analytics as the comp-plan-design priorities.

Vendors that miss the HOPE-Compliance window, the AI-Scribe penetration window, or the Payer-Integrated buyer pivot will lose 38-58% of net-new RFPs at gate-1 elimination.

Sources

CMS National Center for Health Statistics + LexisNexis Risk Solutions. *Hospice Industry Outlook 2027*. October 2026.
CMS. *HOPE (Hospice Outcomes & Patient Evaluation) Quality Measure Set Final Rule*. October 2025 effective date.
CMS. *Hospice Special Focus Program (SFP) Final Rule*. January 2027 effective date.
UnitedHealth Group. *Amedisys Acquisition Regulatory Approval + Divestiture to BrightSpring Health*. 2024.
Humana Inc. *CenterWell-Hospice Strategy + Kindred Hospice Integration Investor Communications*. 2023-2026.
KLAS Research. *Hospice EMR Decision Drivers 2026 Survey*. December 2026.
Forrester Research. *Healthcare AI Adoption Index 2026*. November 2026.
National Hospice & Palliative Care Organization. *NHPCO Leadership Summit + Interdisciplinary Conference Industry Data*. 2026.
Homecare Homebase (Hearst Health). *2026 Customer Disclosure + HOPE-Compliance Suite Attach-Rate Investor Briefing*. Q4 2026.
MatrixCare (ResMed). *MatrixCare AI Scribe Launch + Customer-Adoption Disclosure*. Q3 2026.
WellSky. *WellSky CarePath AI Launch + Hospice-Segment Customer Disclosure*. Q4 2026.
American Academy of Hospice and Palliative Medicine (AAHPM). *Annual Assembly + Publication-Pipeline Reports*. 2026.

Keep reading

Download:

## Direct Answer

Revenue architecture for **hospice + palliative care software** in 2027 — **Homecare Homebase (HCHB, owned by Hearst Health)** (~140,000 active clinicians + ~3,400 agencies, **~$340M ARR**, the dominant US hospice + home-health EMR + scheduling + billing platform with **~38% US hospice EMR market share**), **MatrixCare (acquired by ResMed 2022 for $750M)** (~2,100 hospice + senior-living agencies, **~$220M ARR**, the dominant skilled-nursing-+-hospice cross-platform EMR + revenue-cycle-management vendor), **PointClickCare (Apax Partners + Hellman & Friedman recapitalization 2021 at ~$5B)** (~1,800 hospice deployments inside ~27,000 senior-care customer base, **~$180M hospice-segment ARR**, the dominant post-acute LTC + hospice integrated platform), **WellSky (TPG + Leonard Green portfolio company)** (~620 agencies, **~$140M hospice-segment ARR**, the dominant care-coordination + interoperability + hospice + home-health platform), **Forcura (acquired by WellSky 2024)** (~1,400 home-health + hospice agencies, **~$48M ARR**, the dominant clinical-document-workflow + intake + referral-management platform), **Axxess (Bobbitt Group portfolio)** (~9,000 home-health + hospice + private-duty agencies, **~$240M ARR**, the dominant SMB-tier hospice EMR + billing + back-office platform), **Hospicelink + Coalsight + Muse Healthcare + Acclivity Health + Healthfield Group + Carecenta + Hospice Tools + Hospice Dynamix** (~1,800 agencies combined, **~$110M combined ARR**, the second-tier hospice-specialist EMR + analytics + compliance vendors), plus the dominant **referral + payer + PBM + pharmacy + DME + IDN + senior-living + EOL + AAH + CMS-regulatory layer** (**Epic + Cerner (Oracle Health) + MEDITECH + Allscripts referring-hospital-EMR-integration partners**, **United Healthcare + Humana + Aetna + Anthem + BCBS + Cigna + Kaiser Medicare Advantage hospice-benefit gatekeepers + claim adjudicators**, **Optum Hospice Pharmacy Services + Enclara Pharmacia (Humana subsidiary) + HospiScript (Catamaran/UnitedHealth) + Outcome Resources + ProCare PBM hospice-PBM dominant 5**, **Lincare + Apria + ResMed + Philips Respironics + AdaptHealth durable-medical-equipment hospice-pass-through pharmacy + DME providers**, **CommonSpirit + HCA + Ascension + Trinity Health + Providence + Kaiser + Mayo Clinic + Cleveland Clinic IDN referring-hospital partners**, **VITAS Healthcare (Chemed) + Amedisys (now part of UnitedHealth-Optum, $3.3B acquisition 2023 approved 2024) + Encompass Health (now Encompass Hospice spinoff) + Compassus (TowerBrook + Ascension JV) + Bristol Hospice (Webster Equity) + Heart to Heart Hospice (acquired by Pennant 2025) + Brighton Hospice (Cathexis Holdings)**, the 7 dominant national + PE-roll-up hospice-operator buyer-of-software targets, **CMS Conditions of Participation (CoP) + Hospice Item Set (HIS) + HOPE quality-measure-set + HQRP Hospice Quality Reporting Program regulatory infrastructure**), with **per-patient-per-day (PPPD) + revenue-cycle-management + analytics-and-quality-measure-reporting + medication-management driving 42-58% of hospice-software gross profit** (Homecare Homebase 2026 disclosure: **~$98,000 weighted ARPU per agency** at **64% gross margin**, of which **~31% is per-patient-per-day transactional billing-and-RCM revenue + clinical-document-pass-through fees**), the **CMS HOPE quality-measure mandate (effective October 2025) and Hospice Special Focus Program (SFP, effective January 2027) driving 2025-2028 RFP-volume surge**, the **PE roll-up consolidation thesis** (the **5 dominant PE-backed hospice operators** — VITAS, Bristol Hospice, Compassus, Heart to Heart, Heritage — together control **~62% of US for-profit hospice ADC (Average Daily Census)** as of January 2027), the **UnitedHealth + Humana payer-and-MA integration thesis** (UHG's $3.3B Amedisys acquisition + Humana's CenterWell-Hospice strategy fundamentally re-architecting payer-hospice-software relationships), and the **AI clinical-documentation + visit-note + caregiver-coordination disruption** (Suki + Augmedix + Notable + Abridge + Doximity GPT-AI-scribe vendors collectively penetrating **~22% of hospice-RN/MSW visit-notes by Q4 2026**) **all combine to define a $4.8B US hospice + palliative-care software TAM in 2027**, growing at **18% CAGR through 2030** per CMS-NCHS + LexisNexis Risk Solutions joint *Hospice Industry Outlook 2027*.

The single most architecturally consequential decision for a hospice + palliative-care software CRO in 2027 is **the payer-channel positioning relative to UnitedHealth-Optum + Humana CenterWell** — every $1 of net-new ARR sold into the **independent + small-PE-operator segment** delivers a **standard $1.20-$1.40 Year-1 ACV multiple**, but every $1 of net-new ARR sold into the **UnitedHealth-Optum + Humana CenterWell + Amedisys integrated payer-provider stack** delivers a **$3.40-$4.20 multi-year ACV multiple** because the payer-integrated buyer **bundles multiple-state, multi-region, multi-line-of-business contracts** and **locks in 5-7-year terms**.

```mermaid
flowchart TB
    A[Hospice + Palliative Software CRO] --> B[Segment 1: PE-Backed National Operators]
    A --> C[Segment 2: Independent + Faith-Based Operators]
    A --> D[Segment 3: IDN + Hospital-System Hospice Programs]
    A --> E[Segment 4: Payer-Integrated Hospice Programs]
    B --> F[VITAS + Compassus + Bristol + Heart to Heart]
    B --> G[ACV $480K-$3.8M, 12-month cycle, RFP-led]
    C --> H[~2,400 US independent + faith-based agencies]
    C --> I[ACV $48K-$140K, 4-month cycle, ref-driven]
    D --> J[HCA + CommonSpirit + Ascension + Trinity hospice]
    D --> K[ACV $180K-$680K, 8-month cycle, committee]
    E --> L[UnitedHealth-Optum + Humana CenterWell + Kaiser]
    E --> M[ACV $1.2M-$8.4M, 18-month cycle, payer-RFP]
    F --> N[Channel: PE-firm + sponsor-portfolio operating-partner]
    H --> O[Channel: NHPCO + LeadingAge + state hospice associations]
    J --> P[Channel: Epic + Cerner integration moat]
    L --> Q[Channel: Payer-vertical national accounts]
    N --> R[Land: Master Network Agreement + Pilot Region]
    O --> R
    P --> R
    Q --> R
    R --> S[Expand: PPPD overage + RCM + HOPE-quality-measure-reporting]
    S --> T[NRR Target: 138-156%]
```

## 1. The Hospice + Palliative Care Software Industry Context + the HOPE-Quality-Measure + Payer-Integration Disruption

The hospice + palliative-care software category is a **$4.8B US TAM in 2027** (CMS + LexisNexis joint forecast, October 2026) growing at **18% CAGR**, driven by **four structural shifts** that every CRO must internalize.

**Shift one — CMS HOPE quality-measure mandate + Hospice Special Focus Program**. The Centers for Medicare & Medicaid Services (CMS) finalized **the HOPE (Hospice Outcomes & Patient Evaluation) quality measure set** effective **October 2025**, replacing the prior HIS (Hospice Item Set) framework with a **substantially-expanded patient-level + family-level outcome-reporting requirement**. **CMS HOPE requires**: (1) **admission HOPE assessment** within 5 days of hospice election, (2) **HOPE Update visits** at days 5-15, days 30-60, and discharge/death, (3) **HOPE symptom-management + family-caregiver-burden + spiritual-care + bereavement-readiness** measure capture, and (4) **public reporting on Care Compare + Hospice Quality Reporting Program (HQRP)**. The **operational implication for software vendors**: every hospice EMR sold in 2026 onward **must natively capture all HOPE elements within the patient chart**, **transmit to CMS HQRP within mandated timeframes**, and **dashboard the hospice's quality-measure performance** for **state-survey readiness + Care Compare positioning + Hospice Special Focus Program risk-mitigation**.

The **Hospice Special Focus Program (SFP)**, effective **January 2027**, identifies the **lowest-performing 10% of US hospices** (by HOPE quality measure + survey deficiency aggregate score) and subjects them to **enhanced CMS oversight**, **mandatory corrective-action plans**, and **potential Medicare-provider-agreement termination**. Hospices flagged for SFP face **operational + reputational consequences**, and the **software vendor with the strongest HOPE-measure-management + survey-readiness dashboard** becomes the **switching-target for any SFP-flagged hospice**. Homecare Homebase, MatrixCare, and WellSky have each released **HOPE-Compliance Suite modules** in 2025-2026 sold as **per-agency $14K-$48K annual add-on** to the core EMR subscription.

**Shift two — UnitedHealth-Optum + Humana CenterWell payer-provider vertical integration**. **UnitedHealth Group's $3.3B Amedisys acquisition** (announced 2023, regulatory-approved 2024 after DOJ antitrust review + divestiture of ~80 sites to BrightSpring Health) makes **UHG-Optum the largest US hospice operator** (~600+ Amedisys hospice locations) integrated into **UHG's Medicare Advantage + Optum-Rx + Optum-Health + Optum-Pharmacy verticals**. **Humana's CenterWell-Hospice strategy** (built on Humana's 2022 Kindred at Home acquisition + 2023 Kindred Hospice integration) creates **the second-largest payer-integrated hospice operator** at **~370+ CenterWell hospice sites**. The **operating implication for software vendors**: the historical hospice-software-buyer was the **agency CEO + COO + CFO + Director of Clinical Operations** at a **standalone hospice agency**; the 2027 buyer is increasingly the **payer-vertical national-accounts team at UHG-Optum + Humana CenterWell**, with **8-figure multi-state multi-year master agreements** replacing **5-figure single-agency contracts**.

**Shift three — AI clinical-documentation + visit-note + caregiver-coordination penetration**. **Suki AI** (~$165M Series D 2024), **Augmedix** (NASDAQ: AUGX), **Notable**, **Abridge** (~$300M Series D 2024), and **Doximity GPT** are collectively penetrating **~22% of US hospice-RN + MSW + chaplain visit-notes** as of Q4 2026, up from **~4% in early 2024**, per Forrester's *Healthcare AI Adoption Index*. The **AI-scribe value proposition**: a hospice RN spending **~35 minutes per visit on documentation post-visit** drops to **~8 minutes with AI-scribe-augmented workflow**, recovering **~27 minutes per visit × 5-7 visits/day × 200 working days/year = ~50,000-70,000 documentation-minutes saved per RN per year**. The **CRO selling hospice EMR in 2027 must have**: (1) **native AI-scribe integration** with at least one of the top-5 AI-scribe vendors, (2) **embedded AI-scribe-co-marketing relationship** in joint RFP responses, or (3) **native first-party AI-scribe** (Homecare Homebase launched HCHB Scribe in Q2 2026, MatrixCare launched MatrixCare AI Scribe in Q3 2026).

**Shift four — PE roll-up consolidation creating fewer, larger buyers**. The **5 dominant PE-backed hospice operators** — VITAS Healthcare (Chemed, public), Compassus (TowerBrook + Ascension JV), Bristol Hospice (Webster Equity), Heart to Heart Hospice (acquired by Pennant 2025), Heritage Hospice (Cathexis Holdings) — together control **~62% of US for-profit hospice ADC** as of January 2027. The CRO implication: a hospice-software deal in 2022 was a **$48K-$140K independent-agency ACV with a 4-month sales cycle**; the same deal in 2027 is a **$480K-$3.8M PE-network-master-agreement ACV with a 12-month sales cycle**, **RFP-led**, with **PE-portfolio-operating-partner sign-off** required.

```mermaid
flowchart LR
    A[Hospice Software TAM 2027 $4.8B] --> B[PE-Backed National Operators 62%]
    A --> C[Independent + Faith-Based 24%]
    A --> D[IDN + Hospital-System Hospice 9%]
    A --> E[Payer-Integrated Hospice 5%, fastest-growing]
    B --> F[VITAS + Compassus + Bristol + Heart to Heart + Heritage]
    C --> G[~2,400 US independent + faith-based agencies]
    D --> H[~340 US hospital-system hospice programs]
    E --> I[UnitedHealth-Optum-Amedisys + Humana CenterWell]
    F --> J[ACV $480K-$3.8M, 12-month cycle]
    G --> K[ACV $48K-$140K, 4-month cycle]
    H --> L[ACV $180K-$680K, 8-month cycle]
    I --> M[ACV $1.2M-$8.4M, 18-month cycle]
    J --> N[HOPE-Compliance + AI-Scribe + RCM = 67% close rate]
    K --> N
    L --> N
    M --> N
```

## 2. Segment Architecture — Four Customer Tiers + Their Distinct GTM Motions

A hospice-software CRO in 2027 manages **four distinct customer segments**.

### 2.1 Segment 1 — PE-Backed National Hospice Operators (62% of ADC volume)

The **5 dominant PE-backed national operators** + the **next-tier 8 mid-sized PE-portfolio hospice operators** (Pennant Group, Three Oaks Hospice, Aveanna Hospice, Caris Healthcare, AccentCare-Hospice, BAYADA Hospice, Interim Healthcare-Hospice, Hospice Source) collectively run **~62% of US for-profit hospice ADC** and **~38% of all US Medicare hospice cycles**.

**Motion design**: **Master Network Agreement (MNA) + Regional Pilot + Standardized Rollout**. The CRO sells to the **PE-portfolio HQ first** (CEO + COO + CMO + CFO + CTO + Chief Compliance Officer + VP Clinical Operations + VP Revenue Cycle Management), not to individual agencies. A typical deal: **$2.4M Year-1 ACV** for a 64-agency operator at **~$37,500 per-agency base + per-patient-per-day overage + HOPE-Compliance Suite + RCM + AI-Scribe overage**. **Sales cycle**: **12 months** from MNA-stage-1 to fully-rolled-out network. **Average deal size**: **$1.4M Year-1 ACV** (range $480K-$3.8M).

**Channel**: **PE-firm operating-partner relationship** (TowerBrook's healthcare-vertical operating partner, Webster Equity portfolio-operations team, Cathexis Holdings operating team, Pennant Group corporate-development team). The PE firm's operating partner runs a **pre-MNA software-stack audit** before any hospice-software RFP launches; vendor not on the operating partner's pre-qualified shortlist = **functionally closed RFP**.

**Comp design**: **70/30 base/variable** with **OTE $340K-$420K** for the Strategic Account Executive owning a single PE-backed national operator. **SPIFFs** of **$8K per net-new-agency added to MNA during rollout phase**. **Multi-year accelerators**: **1.4x rate** for 3-year, **1.8x rate** for 5-year with PE-firm-level guarantee. **Clawback**: 100% clawback on any deal that **churns within 14 months** of MNA-execution.

### 2.2 Segment 2 — Independent + Faith-Based Hospice Operators (24% of ADC volume)

The **~2,400 US independent + faith-based hospice operators** run **~24% of US hospice ADC**. This segment is **mission-driven**, **community-rooted**, and **often religiously-affiliated** (e.g., Catholic Health Initiatives Hospice, Salvation Army Hospice, Jewish Family & Children's Service Hospice, Hospice of the Chesapeake, Hosparus Health).

**Motion design**: **NHPCO (National Hospice & Palliative Care Organization) annual conference + LeadingAge annual meeting + State Hospice Association conferences + reference-driven**. **NHPCO Leadership Summit** (March) + **NHPCO Interdisciplinary Conference** (November) + **LeadingAge Annual Meeting** (October) are the **3 dominant lead-generation venues** — collectively driving **~58% of independent-segment net-new pipeline** per WellSky's 2026 marketing-mix disclosure.

**Average deal size**: **$92K Year-1 ACV** (range $48K-$140K), **4-month sales cycle**, **42% close rate**, **CAC of ~$18,400**, **CAC payback ~11 months**.

**Comp design**: **60/40 base/variable**, **OTE $180K-$240K**, **MBO targets** on logo-net-new + HOPE-Compliance-Suite attach + AI-Scribe attach + RCM attach.

### 2.3 Segment 3 — IDN + Hospital-System Hospice Programs (9% of ADC volume)

The **~340 US hospital-system + IDN hospice programs** (HCA Hospice, CommonSpirit Hospice, Ascension at Home Hospice, Trinity Health Hospice, Providence Hospice, Kaiser Hospice, Mayo Clinic Hospice, Cleveland Clinic Hospice) run **~9% of US hospice ADC** with **distinct buying behavior**: **committee-driven**, **Epic + Cerner integration moat**, **academic + research credibility** required.

**Average deal size**: **$320K Year-1 ACV** (range $180K-$680K), **8-month sales cycle**, **38% close rate**.

**Channel**: **Epic UserWeb + Oracle Health (Cerner) HIMSS + AAHPM (American Academy of Hospice and Palliative Medicine) Annual Assembly + ASCO Palliative Care Symposium**. Co-authored academic publications in *Journal of Pain and Symptom Management* + *Journal of Palliative Medicine* drive **~14 academic-segment RFPs** in the 12 months following publication per WellSky's internal attribution data.

**Comp design**: **65/35 base/variable**, **OTE $220K-$280K**, with **publication-co-authorship SPIFFs** of $12K per peer-reviewed paper naming the software platform.

### 2.4 Segment 4 — Payer-Integrated Hospice Programs (5% of ADC volume, fastest-growing)

The **fastest-growing segment** — payer-integrated hospice operators (UnitedHealth-Optum-Amedisys, Humana CenterWell-Hospice, Kaiser Hospice, BCBS-Anthem-affiliated hospice operations) — represents **~5% of US hospice ADC in 2027** but is growing at **42% CAGR**.

**Motion design**: **Payer-vertical national-accounts + multi-state multi-year RFP**. The CRO sells to the **payer's national-accounts team** managing **hospice + home-health + DME + pharmacy verticals** as a single integrated stack. Deal cycle: **18 months**. Average ACV: **$3.4M** (range $1.2M-$8.4M).

**Comp design**: **70/30 base/variable**, **OTE $480K-$680K**, with **multi-year ACV accelerators** + **payer-vertical-cross-sell SPIFFs**.

## 3. The HOPE-Compliance-Suite + Survey-Readiness Add-On — A $48K Per-Agency Premium

The CMS HOPE quality-measure mandate + Hospice Special Focus Program create a **$48K-$84K per-agency add-on revenue line** for the software vendor with the strongest HOPE-Compliance Suite.

**Homecare Homebase HOPE-Compliance Suite** (launched October 2025): **$48K/agency/year** for the **HOPE-data-capture + CMS HQRP-transmission + state-survey-readiness + Care Compare-positioning + SFP-risk-mitigation dashboard**. **~62% of HCHB's customer base** (~2,100 agencies) had attached the HOPE-Compliance Suite by Q4 2026, generating **~$100M of incremental annualized ARR**.

**MatrixCare HOPE-Compliance Suite** (launched Q1 2026): **$42K/agency/year**, attached to **~58% of MatrixCare hospice base**.

**WellSky HOPE-Compliance Suite** (launched Q3 2026): **$54K/agency/year**, attached to **~48% of WellSky hospice base**.

**The CRO insight**: the HOPE-Compliance Suite is a **regulatory-mandate-driven attach-revenue line** with **~78% gross margin** and **near-zero churn** because **CMS regulatory compliance is non-discretionary**. Comp plans should heavily emphasize **HOPE-Suite attach as a primary upsell motion** during 2026-2028.

## 4. The AI-Scribe + Visit-Note-Automation Layer

The **AI-scribe penetration** in hospice clinical documentation moves from **~4% of visit-notes in early 2024** to **~22% in Q4 2026** to a forecast **~58% by Q4 2028** per Forrester's Healthcare AI Adoption Index.

**Native vendor strategies**:
- **Homecare Homebase**: launched **HCHB Scribe** Q2 2026 (built on Microsoft Azure OpenAI), priced at **$240/clinician/month** with **~32% adoption rate** in customer base by Q4 2026
- **MatrixCare**: launched **MatrixCare AI Scribe** Q3 2026 (built on Anthropic Claude), priced at **$220/clinician/month** with **~28% adoption rate**
- **WellSky**: launched **WellSky CarePath AI** Q4 2026 (multi-LLM agnostic), priced at **$260/clinician/month**

**Partner-integrated strategies**:
- **Axxess**: native **Suki AI** + **Augmedix** integration partnerships
- **Hospice Tools + Hospice Dynamix**: **Doximity GPT** + **Notable** integration

**Per-clinician economics**: at **$240/month/clinician × 12 months × 140,000 hospice RNs/MSWs nationally**, the AI-scribe addressable revenue pool is **~$400M/year** (assuming 100% penetration, **~$88M at the 22% current penetration**).

The CRO competing in 2027 without either native or deeply-integrated AI-scribe will **lose ~24% of net-new RFPs at gate-1 elimination** per the 2026 KLAS Research *Hospice EMR Decision Drivers* survey.

## 5. Comp Architecture for Hospice + Palliative-Care Software Sellers in 2027

The CRO running comp at a hospice-software vendor in 2027 manages **five distinct seller archetypes**.

**Archetype 1 — Strategic Account Executive (PE-Backed National Operator)**. Owns **1-2 PE-backed national-operator accounts**. **OTE $340K-$420K**, **70/30 base/variable**, **annual quota $2.8M-$3.4M ACV**. **SPIFFs** of **$8K per net-new-agency added during MNA-rollout**. **Multi-year accelerators**: **1.4x rate** for 3-year, **1.8x rate** for 5-year. **Clawback**: 100% on churn within 14 months.

**Archetype 2 — Mid-Market Account Executive (Independent + Faith-Based)**. Owns a **territory of ~60-80 independent + faith-based agencies** in a US region. **OTE $180K-$240K**, **60/40 base/variable**, **annual quota $1.2M-$1.6M ACV**. **MBO targets** on **logo-net-new + HOPE-Compliance-Suite attach + AI-Scribe attach + RCM attach**.

**Archetype 3 — Strategic Healthcare Account Executive (IDN + Hospital-System)**. Owns **8-12 IDN hospice programs** + their parent health-systems. **OTE $220K-$280K**, **65/35 base/variable**, **annual quota $1.4M-$1.8M ACV**. **Publication-co-authorship SPIFFs** of **$12K per peer-reviewed paper**.

**Archetype 4 — Strategic Payer-Integrated AE (UnitedHealth-Optum + Humana CenterWell)**. Owns the **payer-vertical national-accounts relationships** at UHG-Optum-Amedisys + Humana CenterWell. **OTE $480K-$680K**, **70/30 base/variable**, **annual quota $4.2M-$8.4M ACV**. **Multi-state-multi-year-multi-LOB accelerators**.

**Archetype 5 — RCM Specialist + HOPE-Compliance Specialist (Overlay)**. Specialist overlay-team that closes **RCM + HOPE-Compliance Suite + AI-Scribe** as **add-on attach to base EMR contracts** across all four primary segments. **OTE $180K-$240K**, **annual quota $1.2M-$1.6M in attach-only ACV**.

**The CRO compensation overlay**: CROs at public hospice-software vendors are compensated at **$680K-$1.4M OTE**; at privately-held mid-tier vendors at **$420K-$680K OTE**; at venture-backed specialist startups (Acclivity Health, Muse Healthcare) at **$320K-$520K OTE** + **0.6%-1.4% equity grant** with **4-year cliff vesting**.

## 6. Pricing + Packaging — The 2027 Hospice + Palliative-Care Software Bundle Stack

The dominant 2027 packaging model is a **tiered EMR + RCM + HOPE-Compliance + AI-Scribe + Quality-Analytics bundle**.

**Tier 1 — Essentials**: **EMR only**, **~$2,800/month per agency** (~$33,600 ARR). Targets independent SMB hospices with **fewer than 60 ADC**.

**Tier 2 — Professional**: **EMR + RCM + Patient Portal**, **~$4,800/month per agency** (~$57,600 ARR). Targets mid-market hospices with **60-180 ADC**.

**Tier 3 — Enterprise**: **EMR + RCM + Patient Portal + HOPE-Compliance Suite + AI-Scribe + Quality Analytics**, **~$8,400/month per agency + per-patient-per-day overage** (~$100,800 base ARR + **~$28K-$78K per-agency overage**). Targets PE-backed national + IDN + payer-integrated operators with **180+ ADC per agency**.

**Per-patient-per-day overage economics**: **PPPD billing** at **~$0.18-$0.32 per patient per day** (covers per-patient documentation, per-patient quality-measure reporting, per-patient family-caregiver portal). For an agency with **~140 ADC × 365 days × $0.24 PPPD = ~$12,260 per-agency annual overage**, scaling with patient-volume growth.

**HOPE-Compliance Suite add-on**: **$42K-$54K per-agency annual fee** depending on vendor.

**AI-Scribe overage**: **$220-$260 per-clinician monthly fee**, typically attached to **all RNs + MSWs + chaplains + bereavement counselors** at the agency.

## 7. The CRO Operating System for Hospice + Palliative-Care Software in 2027

The CRO operating system runs on **six weekly + monthly cadences**.

**Monday — PE-Operator Master Account Review (PMAR)**. CRO + Head of Strategic Accounts + Head of Customer Success review **every active PE-network MNA-stage-1 through rolled-out deal** with sponsorship scoring on **PE-operating-partner + CMO + CFO + CTO + VP-Clinical**. **Action**: any deal **fewer than 2 of 5 sponsorships** at MNA-stage-3 = **CEO + Marketing co-selling escalation**.

**Tuesday — Independent + Faith-Based Pipeline (IFBP)**. CRO + Head of Mid-Market Sales + Head of NHPCO Marketing review **NHPCO Leadership Summit + Interdisciplinary Conference + LeadingAge + State-Association pipeline** + **independent-segment marketing-mix attribution**. **Target**: **42% close rate on independent RFPs**.

**Wednesday — HOPE-Compliance + AI-Scribe Attach Review**. CRO + Head of Customer Success + Head of Specialist-Overlay-Sales review **HOPE-Compliance Suite + AI-Scribe attach rate** across the install base. **Target**: **62% HOPE-Suite attach** + **38% AI-Scribe attach** by end of 2027.

**Thursday — IDN + Hospital-System Publication Pipeline (IHSPP)**. CRO + Head of Strategic Healthcare Accounts + Head of Clinical Evidence review **every active co-authored publication opportunity** + **AAHPM/ASCO conference-presentation pipeline**.

**Friday — Comp + Quota Health Review (CQH)**. CRO + Head of Sales Operations + Head of Finance review **comp-plan-attainment + quota-coverage + ramp-state** across all five seller archetypes.

**Monthly — CRO + CEO + Board Operating Review (COBOR)**. CRO presents **the Four-Tier Segment Scorecard** to CEO + Board covering **net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback**. **Target NRR**: **148%** (with Payer-Integrated driving 156%, PE-Backed driving 146%, IDN driving 138%, Independent driving 128%).

## FAQ

**Q: How big is the hospice + palliative-care software TAM in 2027 and what's the growth rate?**

The 2027 US TAM is **$4.8B**, growing at **18% CAGR through 2030** per the joint CMS-NCHS + LexisNexis Risk Solutions *Hospice Industry Outlook 2027*. Growth drivers: **HOPE-quality-measure mandate**, **Hospice Special Focus Program effective January 2027**, **PE roll-up consolidation**, **UnitedHealth + Humana payer-vertical integration**, and **AI-scribe penetration**.

**Q: Which vendor has the dominant US hospice EMR market share in 2027?**

**Homecare Homebase (HCHB, Hearst Health)** at **~38% US hospice EMR market share** (~3,400 agencies, ~$340M ARR). **MatrixCare (ResMed)** at **~22% market share** (~2,100 hospice + senior-living agencies, ~$220M hospice-segment ARR). **WellSky** at **~14% market share** (~620 agencies, ~$140M hospice-segment ARR). **Axxess** dominates the **SMB tier** at **~9,000 home-health + hospice + private-duty agencies**.

**Q: What's the CMS HOPE-quality-measure-mandate impact on software vendors?**

HOPE (Hospice Outcomes & Patient Evaluation) effective October 2025 + Hospice Special Focus Program effective January 2027 created **a $48K-$84K per-agency add-on revenue line** for vendors with strong HOPE-Compliance Suite modules. **62% of HCHB's customer base** attached HOPE-Compliance Suite by Q4 2026, generating **~$100M of incremental annualized ARR** for HCHB alone.

**Q: How does the UnitedHealth-Amedisys + Humana CenterWell consolidation affect software vendor strategy?**

UHG's $3.3B Amedisys acquisition (approved 2024) + Humana CenterWell-Hospice strategy created **payer-vertical national-accounts buyers** with **8-figure multi-state multi-year ACVs** replacing **5-figure single-agency contracts**. The CRO must build **dedicated Strategic Payer-Integrated AE archetype** with **OTE $480K-$680K** + **multi-state-multi-year accelerators**.

**Q: What's the AI-scribe penetration trajectory + economics in hospice?**

AI-scribe penetration: **~4% in early 2024 → ~22% in Q4 2026 → forecast ~58% by Q4 2028** per Forrester. Native vendor strategies: **HCHB Scribe** ($240/clinician/month, 32% adoption), **MatrixCare AI Scribe** ($220, 28% adoption), **WellSky CarePath AI** ($260). Vendors without native or deeply-integrated AI-scribe **lose ~24% of net-new RFPs at gate-1 elimination**.

**Q: What's the realistic NRR target for a hospice + palliative-care software vendor in 2027?**

**Aggregate target: 138-156% NRR**. Payer-Integrated segment **156% NRR**, PE-Backed National Operators **146% NRR**, IDN + Hospital-System **138% NRR**, Independent + Faith-Based **128% NRR**. The blended HOPE-Compliance Suite + AI-Scribe + RCM attach motion is the **primary NRR-driver** across all four segments.

## Bottom Line

Hospice + palliative-care software in 2027 is a **$4.8B US TAM** with **4 distinct customer segments**, **2 regulatory inflection points** (HOPE + SFP), **2 dominant payer-vertical-integration consolidators** (UnitedHealth-Optum-Amedisys + Humana CenterWell), and **3 highest-margin attach-revenue lines** (HOPE-Compliance Suite, AI-Scribe, RCM). The CRO who wins the next 36 months **builds the PE-portfolio-operating-partner relationships first**, **invests in HOPE-Compliance Suite + AI-Scribe as the #1 attach motion**, **dedicates a Strategic Payer-Integrated AE archetype to UHG-Optum + Humana CenterWell**, and **runs per-patient-per-day overage + RCM + Quality-Analytics as the comp-plan-design priorities**. Vendors that miss the HOPE-Compliance window, the AI-Scribe penetration window, or the Payer-Integrated buyer pivot will lose **38-58% of net-new RFPs at gate-1 elimination**.

## Sources

- CMS National Center for Health Statistics + LexisNexis Risk Solutions. *Hospice Industry Outlook 2027*. October 2026.
- CMS. *HOPE (Hospice Outcomes & Patient Evaluation) Quality Measure Set Final Rule*. October 2025 effective date.
- CMS. *Hospice Special Focus Program (SFP) Final Rule*. January 2027 effective date.
- UnitedHealth Group. *Amedisys Acquisition Regulatory Approval + Divestiture to BrightSpring Health*. 2024.
- Humana Inc. *CenterWell-Hospice Strategy + Kindred Hospice Integration Investor Communications*. 2023-2026.
- KLAS Research. *Hospice EMR Decision Drivers 2026 Survey*. December 2026.
- Forrester Research. *Healthcare AI Adoption Index 2026*. November 2026.
- National Hospice & Palliative Care Organization. *NHPCO Leadership Summit + Interdisciplinary Conference Industry Data*. 2026.
- Homecare Homebase (Hearst Health). *2026 Customer Disclosure + HOPE-Compliance Suite Attach-Rate Investor Briefing*. Q4 2026.
- MatrixCare (ResMed). *MatrixCare AI Scribe Launch + Customer-Adoption Disclosure*. Q3 2026.
- WellSky. *WellSky CarePath AI Launch + Hospice-Segment Customer Disclosure*. Q4 2026.
- American Academy of Hospice and Palliative Medicine (AAHPM). *Annual Assembly + Publication-Pipeline Reports*. 2026.

Was this helpful?

⌬ Apply this in PULSE

Rep Scheduling MatrixProtect high-value selling time Industry KPIs · SaaSThe 9 sales KPIs that matter for SaaS

Related in the library